Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
✍ Scribed by Daryl C. Drummond; Charles O. Noble; Mark E. Hayes; John W. Park; Dmitri B. Kirpotin
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 753 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
✦ Synopsis
Liposomes represent a widely varied and malleable class of drug carriers generally characterized by the presence of one or more amphiphile bilayers enclosing an interior aqueous space. Thus, the pharmacological profile of a particular liposomal drug formulation is a function not only of the properties of the encapsulated drug, but to a significant extent of the pharmacokinetics, biodistribution, and drug release rates of the individual carrier. Various physicochemical properties of the liposomal carriers, the drug encapsulation and retention strategies utilized, and the properties of the drugs chosen for encapsulation, all play an important role in determining the effectiveness of a particular liposomal drug. These properties should be carefully tailored to the specific drug, and to the application for which the therapeutic is being designed. Liposomal carriers are also amenable to additional modifications, including the conjugation of targeting ligands or environment-sensitive triggers for increasing the bioavailability of the drug specifically at the site of disease. This review describes the rationale for selecting optimal strategies of liposomal drug formulations with respect to drug encapsulation, retention, and release, and how these strategies can be applied to maximize therapeutic benefit in vivo.
📜 SIMILAR VOLUMES
## Abstract The purpose of this study was to determine if MnSO~4~/doxorubicin (DOX) loaded liposomes could be used for in vivo monitoring of liposome concentration distribution and drug release using MRI. In vitro results show that __T__~1~ shortening correlates with MnSO~4~ concentration. Using a
## Abstract Effective cancer chemotherapy depends on the delivery of therapeutic drugs to cancer cells at cytotoxic concentrations. However, physiologic barriers, such as variable vessel permeability, high interstitial fluid pressure, and heterogeneous perfusion, make it difficult to achieve that g
Since the discovery of liposomes or lipid vesicles derived from self-forming enclosed lipid bilayers upon hydration, liposome drug delivery systems have played a signi®cant role in formulation of potent drugs to improve therapeutics. Currently, most of these liposome formulations are designed to red
## Abstract We used the membrane‐impermeable nitroxyl radical 4‐trimethylammonium‐2,2,6,6‐tetramethylpiperidine‐1‐oxyliodide (CAT‐1) as a model drug encapsulated in liposomes in order to separately map the 2D distribution of both liposomal‐encapsulated CAT‐1 and free CAT‐1. Phantoms were prepared w